Elubrixin
Alternative Names: 656933; Elubrixin tosylate; GSK-656933; SB-656933-AAA; SB-656933-AAFLatest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action CD11b antigen antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Cystic fibrosis; Ulcerative colitis
Most Recent Events
- 29 Feb 2012 Discontinued - Phase-II for Cystic fibrosis in Canada (PO)
- 29 Feb 2012 Discontinued - Phase-II for Cystic fibrosis in France (PO)
- 29 Feb 2012 Discontinued - Phase-II for Cystic fibrosis in Germany (PO)